Virus-based vectors for human vaccine applications
- PMID: 12110228
- DOI: 10.1016/s1359-6446(02)02324-3
Virus-based vectors for human vaccine applications
Abstract
Vaccinology has experienced a dramatic resurgence recently, as traditional methodologies of using attenuated live pathogens or inactivated whole pathogens have been either ineffective or are not an acceptable risk for several disease targets, including HIV and Hepatitis C. Gene-based vaccines can stimulate potent humoral and cellular immune responses, and viral vectors might be an efficient strategy for both delivery of antigen-encoding genes, as well as facilitating and enhancing antigen presentation. Vectors derived from diverse viruses with distinct tropism and gene expression strategies have been developed, and are being evaluated in preclinical and clinical vaccine studies. Virus-based vaccines represent a promising approach for vaccines against infectious and malignant disease.
Comment in
-
Live vectors: are safe but effective vaccines possible?Drug Discov Today. 2002 Aug 15;7(16):854-5. doi: 10.1016/s1359-6446(02)02365-6. Drug Discov Today. 2002. PMID: 12546948 No abstract available.
Similar articles
-
Recombinant viruses as vaccines against viral diseases.Braz J Med Biol Res. 2005 Apr;38(4):509-22. doi: 10.1590/s0100-879x2005000400004. Epub 2005 Apr 13. Braz J Med Biol Res. 2005. PMID: 15962176 Review.
-
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.J Virol. 2018 Aug 16;92(17):e00976-18. doi: 10.1128/JVI.00976-18. Print 2018 Sep 1. J Virol. 2018. PMID: 29925653 Free PMC article.
-
Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors.J Virol. 2001 Jan;75(2):622-7. doi: 10.1128/JVI.75.2.622-627.2001. J Virol. 2001. PMID: 11134275 Free PMC article.
-
Live recombinant vectors for AIDS vaccine development.Curr Mol Med. 2003 May;3(3):273-84. doi: 10.2174/1566524033479816. Curr Mol Med. 2003. PMID: 12699363 Review.
-
Amplicons as vaccine vectors.Curr Gene Ther. 2006 Jun;6(3):383-92. doi: 10.2174/156652306777592009. Curr Gene Ther. 2006. PMID: 16787189 Review.
Cited by
-
The safety of vaccines.Drug Discov Today. 2004 Oct 1;9(19):846-54. doi: 10.1016/S1359-6446(04)03234-9. Drug Discov Today. 2004. PMID: 15381137 Free PMC article. Review.
-
An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.Cancer Gene Ther. 2011 May;18(5):326-35. doi: 10.1038/cgt.2010.82. Epub 2011 Jan 14. Cancer Gene Ther. 2011. PMID: 21233857 Free PMC article.
-
Vaccine adjuvant-elicited CD8+ T cell immunity is co-dependent on T-bet and FOXO1.Cell Rep. 2023 Aug 29;42(8):112911. doi: 10.1016/j.celrep.2023.112911. Epub 2023 Jul 29. Cell Rep. 2023. PMID: 37516968 Free PMC article.
-
Novel approaches to vaccine delivery.Pharm Res. 2004 Sep;21(9):1519-30. doi: 10.1023/b:pham.0000041443.17935.33. Pharm Res. 2004. PMID: 15497674 Free PMC article. Review.
-
A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.Mol Biol Rep. 2011 Aug;38(6):3731-40. doi: 10.1007/s11033-010-0488-1. Epub 2010 Nov 24. Mol Biol Rep. 2011. PMID: 21107723 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical